NCT07173556 2025-09-15A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast CancerQilu Pharmaceutical Co., Ltd.Phase 1/2 Not yet recruiting96 enrolled